Lilly Oncology offers a suite of tools and resources to facilitate treatment with LARTRUVO, and help you provide the best possible care to your patients.
Important information about LARTRUVO.
Information on dosing, premedication requirements, dose modifications, and infusion preparation for LARTRUVO.
A tool to help identify the optimal combination of LARTRUVO vials to reduce wastage.
A series of educational events designed to share knowledge and best practices among the STS community.
The NCCN Guidelines? for STS.
Helpful information for patients to learn what they can expect from treatment with LARTRUVO.
Helpful billing and coding information for LARTRUVO.
Helpful information on the specialty distributors and specialty pharmacy that Lilly has contracted to help get LARTRUVO to customers.
This resource provides suggested guidance on how to populate the CMS-1450 claim form when submitting a claim for the administration of LARTRUVO in the outpatient hospital setting.
This resource provides suggested guidance on how to populate the CMS-1500 claim form when submitting a claim for the administration of LARTRUVO in the physician?s office.
You are now leaving the www.LARTRUVO.com website.
LARTRUVO is indicated, in combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.
This indication is approved under accelerated approval. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.
Please see full Prescribing Information for LARTRUVO.
OR HCP ISI 19OCT2016